US OptionsDetailed Quotes
KROS250117C22500
- 0.14
- 0.000.00%
15min DelayClose Jan 10 16:00 ET
0.00High0.00Low
0.14Open0.14Pre Close0 Volume30 Open Interest22.50Strike Price0.00Turnover221.76%IV55.49%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier6DDays to Expiry0.14Extrinsic Value100Contract SizeAmericanOptions Type0.0827Delta0.0369Gamma104.00Leverage Ratio-0.0495Theta0.0002Rho8.61Eff Leverage0.0028Vega
Keros Therapeutics Stock Discussion
Sign in to post a comment
$Keros Therapeutics (KROS.US)$ turn off your stop losses
1
$Keros Therapeutics (KROS.US)$ what happened 75% down?
1
$Keros Therapeutics (KROS.US)$ this will go back to 40s by Monday 👀👀👀
1
1
🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...
18
3
3
NHP data from $Regeneron Pharmaceuticals (REGN.US)$ 's new slide deck is very relevant for the weight loss space.
Combining pure anti-Myostatin antibodies with Semaglutide was marginally effective in NHPs in preventing muscle loss. I believe that for that reason, $Scholar Rock (SRRK.US)$ and probably also $Biohaven (BHVN.US)$ are likely to disappoint.
Additionally blocking other ligands like Activin A dramatically improves body composition. That is what $Eli Lilly and Co (LLY.US)$ , $Keros Therapeutics (KROS.US)$ ...
Combining pure anti-Myostatin antibodies with Semaglutide was marginally effective in NHPs in preventing muscle loss. I believe that for that reason, $Scholar Rock (SRRK.US)$ and probably also $Biohaven (BHVN.US)$ are likely to disappoint.
Additionally blocking other ligands like Activin A dramatically improves body composition. That is what $Eli Lilly and Co (LLY.US)$ , $Keros Therapeutics (KROS.US)$ ...
3
No comment yet
Tooleye3 OP : - YouTube